Kymera in the News

Read about breakthroughs, clinical advancements, and ongoing work to develop new medicines at Kymera.

Featured Perspectives

Headshot of Karen Weisbach
March 31, 2023
Driving Culture Through Values
Karen Weisbach, PHR, Head of People + Culture
Headshot of Juliet Williams
March 1, 2023
Living Our Core Values – Pioneer: Breaking new ground with a powerful new modality
Juliet Williams, PhD, Head of Research
Headshot of Brian Albarran
April 21, 2023
Small Molecules, Big Impact: Expanding the Universe of Targets
Brian Albarran, PhD, Senior Vice President, Head of Corporate Strategy
Showing 30 news results
August 12, 2024

Dermatology Times: Study Highlights KT-474’s Effectiveness in Targeting IRAK4 for Hidradenitis Suppurativa and Other Inflammatory Diseases

Dermatology Times spoke with Jared Gollob, MD, Chief Medical Officer of Kymera Therapeutics, to discuss the role of IRAK4 expression and degradation in HS, as well as the potential of KT-474 in immuno-inflammatory diseases.

Read More
August 9, 2024

BiotechTV: Nello Mainolfi Shares an Update on Kymera and the Progress of the Protein Degradation Field

Nello gives updates on programs such as IRAK4, STAT6, TYK2, and STAT3, and describes learnings in protein degradation that Kymera has discovered since the last time BiotechTV visited the company one year ago.

Read More
July 23, 2024

Drug Target Review: Women in STEM with Juliet Williams

As part of their series highlighting women in STEM, Drug Target Review spoke to Juliet Williams, Head of Research at Kymera. She discusses what inspired her early passion for science, the power of mentorship and what excites her most about the future of targeted protein degradation – and its potential to deliver results in previously undruggable conditions.

Read More
May 23, 2024

PharmaLeaders: Upending Traditional Wisdom at DDW, an Interview with Nello Mainolfi, PhD

PharmaLeaders had the chance to discuss Kymera’s exciting progress with Founder, President and CEO, Nello Mainolfi, Ph.D.

Read More
March 18, 2024

Boston Business Journal: Biotech Upgrades to New Watertown Digs with Triple the Space

The Boston Business Journal highlighted Kymera’s recent move to enable the expansion of our innovative R&D capabilities and support our growing team’s vibrant on-site presence as we work toward delivering life-changing medicines to patients.

Read More
February 29, 2024

Scrip: Kymera Puts Emphasis On Immunology In New Growth Phase

CEO Nello Mainolfi talked to Scrip about Kymera’s pipeline expansion, which will prioritize oral targeted protein degraders in immunology, including two new assets moving into the clinic.

Read More
January 4, 2024

Endpoints News: Kymera doubles down on protein degraders for immunology, chasing Dupixent and Sotyktu

Looking to further expand the reach of protein degraders beyond cancer, Kymera Therapeutics revealed two new programs Thursday morning that it hopes will compete with some of the hottest immunology drugs on the market.

Read More
December 26, 2023

Genetic Engineering & Biotechnology News: Up-to-$2B Sanofi Collaboration Pays Off for Kymera

Through a pair of recent clinical milestones, Kymera Therapeutics continues to cash in on its up-to-$2 billion collaboration with Sanofi to develop first-in-class targeted protein degradation (TPD) therapies for patients with immune-inflammatory diseases.

Read More
December 11, 2023

BioCentury: Building on dermatology’s recent success

Once cast off by most pharmas and investors, dermatology drug development is experiencing a renaissance. A standout commercial success has put atopic dermatitis on the map. Each new psoriasis therapy is extending efficacy. And emerging drug classes are promising to expand the pool of responders, both within dermatology’s major indications and into new ones.

Read More
December 4, 2023

Nature Reviews Drug Discovery: PROTAC in clinic for autoimmune skin disease

The kinase IRAK4 is a crucial regulator of signalling pathways that control innate immunity. Inhibitors of its kinase activity have been developed for autoimmune diseases but have not shown strong efficacy. Now, in Nature Medicine, Ackerman et al. describe an IRAK4 protein degrader and report encouraging preliminary results in patients with chronic inflammatory skin diseases.

Read More

CONTACT
PRESS RELEASES
COMPANY BACKGROUND

Featured Presentations & Publications

December 10, 2023
Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors
American Society of Hematology (ASH) Annual Meeting and Exposition 2024
November 14, 2023
IRAK4 Degradation vs Inhibition
IRAK4 Program Background
November 13, 2023
Nature Medicine: IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial
Lindsay Ackerman, Gerard Acloque, Sandro Bacchelli, Howard Schwartz, Brian J. Feinstein, et al.